129
Participants
Start Date
November 30, 2014
Primary Completion Date
June 30, 2017
Study Completion Date
July 30, 2017
Spironolactone
The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.
The George Washington University, Washington D.C.
Vanderbilt University Medical Center, Nashville
Kidney Research Institute, University of Washington, Seattle
Brigham and Women's Hospital, Boston
Brigham and Women's Hospital
OTHER
George Washington University
OTHER
Vanderbilt University
OTHER
University of Washington
OTHER
University of Pennsylvania
OTHER